Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference

Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C.

Rhea-AI Summary

Bellerophon Therapeutics (Nasdaq: BLPH) announced that CEO Fabian Tenenbaum will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting March 9, 2021, on the company’s website. Bellerophon focuses on developing innovative therapies for cardiopulmonary and infectious diseases, including its proprietary INOpulse® program, a pulsatile nitric oxide delivery system. For more information, visit bellerophon.com.

Argus Publication session

+0.31% session move Open Argus

Details

News Market Reaction – BLPH

In the trading session that priced this news, BLPH gained 0.31%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse^® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At W2O Group:	At LifeSci Advisors:
Julie Normart	Brian Ritchie
(559) 974-3245	(212) 915-2578
jnormart@w2ogroup.com	britchie@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Bellerophon Therapeutics presenting at the H.C. Wainwright Global Life Sciences Conference?

Bellerophon Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Where can I watch Bellerophon Therapeutics' presentation?

The presentation will be available on-demand on Bellerophon Therapeutics' website starting March 9, 2021.

What is the focus of Bellerophon Therapeutics?

Bellerophon Therapeutics focuses on developing treatments for cardiopulmonary and infectious diseases.

What is the INOpulse® program by Bellerophon?

The INOpulse® program is Bellerophon Therapeutics' proprietary pulsatile nitric oxide delivery system.